As radiopharmaceuticals become a hot global track for innovative oncology drugs, FAP-targeted assets, with both diagnostic and therapeutic potential, have become a focal point of competition among pharmaceutical companies worldwide. As a leading radiopharmaceutical firm, GRAND PHARMA (00512) has recently achieved another significant breakthrough in this field. The company's innovative FAP-targeted radiopharmaceutical, GPN01530-2, has been granted Fast Track Designation (FTD) by the U.S. FDA, making it the first FAP-targeted diagnostic radiopharmaceutical for solid tumors globally to receive this FDA designation. The FTD is primarily awarded to investigational drugs intended to treat serious conditions and address unmet medical needs, aiming to accelerate the review process for high-value pipelines. It is noted that GPN01530-2 had previously received FDA approval to conduct Phase I/II clinical studies for diagnosing solid tumors. This latest FTD designation signifies that U.S. regulators recognize the product's significant potential in solid tumor diagnosis, which is expected to expedite its future development and marketing, benefiting patients worldwide sooner.
Particularly noteworthy is that GPN01530-2 securing the FDA Fast Track designation carries strong industry significance. Amidst the global landscape where major radiopharmaceutical players are heavily investing in FAP-targeted nuclear drugs, an innovative radiopharmaceutical independently developed by a Chinese company has taken the lead in obtaining this important regulatory qualification. This fully demonstrates GRAND PHARMA's R&D capabilities in FAP-targeted innovative radiopharmaceuticals, placing it in the global first tier. It also reflects the Best-in-Class (BIC) development potential of GPN01530-2. Furthermore, as a self-developed RDC product from GRAND PHARMA that has received FDA approval for clinical research, this milestone progress also strongly validates the company's comprehensive strength in building cutting-edge radiopharmaceutical technology platforms, international clinical development, and regulatory filing.
Optimizing FAP Ligand Structure to Unlock Vast Potential in Pan-Cancer Market
According to the announcement, GPN01530-2 is a small-molecule RDC drug targeting Fibroblast Activation Protein (FAP). FAP is not expressed or is expressed at low levels in normal tissues but is highly expressed in 90% of epithelial tumors and Cancer-Associated Fibroblasts (CAFs) within various tumor microenvironments, making it a novel specific target for tumor diagnosis and therapy. The specific expression pattern of FAP makes it an ideal pan-cancer target, broadly covering various solid tumors including lung cancer, colorectal cancer, and pancreatic cancer. It is naturally suited for the development of "diagnosis + therapy" integrated RDC drugs and is considered by the industry as a potential billion-dollar target following PSMA, attracting major multinational pharmaceutical companies like Novartis to actively compete.
Notably, GRAND PHARMA's GPN01530-2 has enhanced its uptake in tumor tissues while reducing uptake in normal tissues by optimizing the structure of the FAP ligand. Compared to both similar FAP-targeted products and the current mainstream PET/CT imaging agent fluorodeoxyglucose (18F-FDG), GPN01530-2 has demonstrated significant advantages, showing strong Best-in-class potential. Based on existing research results, GPN01530-2 exhibits rapid tumor targeting, higher tumor uptake, and superior pharmacokinetic properties compared to other FAP ligands. Additionally, completed IIT human studies show that GPN01530-2 features rapid background clearance and strong, persistent lesion uptake, offering superior clinical image contrast and accurate detection rate of positive lesions compared to 18F-FDG. It is evident that GPN01530-2 significantly improves the diagnostic performance of FAP-targeted RDC drugs, potentially providing a novel tumor diagnostic solution for a broad range of solid tumor patients.
From a market perspective, GPN01530-2 is a product with substantial commercialization potential. Even just estimating the potential replacement market for 18F-FDG, the addressable market exceeds $5 billion, and the number of solid tumor patients it targets is continuously growing. According to GLOBOCAN data, there were approximately 20 million new cancer cases and 9.7 million cancer deaths globally in 2022. It is projected that by 2030, new cancer cases worldwide will approach 24 million, and deaths will approach 12 million. Alongside the growth in patient numbers, the global oncology drug market is also expanding. Frost & Sullivan data predicts the global oncology drug market will reach $702.7 billion by 2035. In this large and continuously expanding tumor diagnosis and treatment market, precise, efficient, and safe integrated solutions are a core industry need, creating a prime competitive opportunity for GPN01530-2. Currently, GPN01530-2 has been approved for clinical research in the U.S. If subsequent development proceeds smoothly, it could become a critical breakthrough in addressing the diagnostic challenges of solid tumors. Leveraging the exclusive policy benefits of FTD, this product could compress its R&D and approval timelines, reshape the solid tumor diagnostic landscape with its significant product advantages, capture the global solid tumor diagnostic market first, and bring new hope to patients worldwide.
Simultaneously, as the first and currently only FAP-targeted solid tumor diagnostic radiopharmaceutical to receive FTD globally, GPN01530-2's significant clinical value and BIC development potential have been recognized by authoritative regulatory bodies. This marks a breakthrough for China's innovative radiopharmaceuticals in the cutting-edge FAP-targeted field, achieving global leadership, aligned standards, and priority benefits. GRAND PHARMA will continue to advance the global R&D and registration of GPN01530-2, leveraging the "China-U.S. dual filing" international registration pathway. On this foundation, the company will further deepen its global development strategy for its radiopharmaceutical anti-tumor segment, actively promote international clinical research and registration for more self-developed innovative radiopharmaceutical products, and continuously enhance its core competitiveness and international influence in the radiopharmaceutical oncology diagnosis and treatment field.
Building a Full-Chain Radiopharmaceutical Ecosystem, Aiming to Export China's Self-Developed Products Globally
The overseas clinical breakthrough of GPN01530-2 is a microcosm of GRAND PHARMA's global strategy implementation in the radiopharmaceutical anti-tumor segment. As one of the earliest innovative pharmaceutical companies in China to establish a full radiopharmaceutical industry chain, GRAND PHARMA has achieved comprehensive coverage across multiple links including R&D, production, distribution, and sales. The company has built a globalized radiopharmaceutical industry chain, with R&D bases centered in Boston and Chengdu, and production bases in Boston, Frankfurt, Singapore, and Chengdu. Its sales network covers over 50 countries and regions globally, with a team of over 1,000 employees in global R&D and production. In terms of product pipeline, focusing on the core concept of integrated tumor diagnosis and therapy, GRAND PHARMA has accumulated 16 innovative radiopharmaceutical products in the R&D and registration stage, covering 5 types of radionuclides including 68Ga, 177Lu, 131I, 90Y, and 89Zr, spanning 7 cancer types such as liver cancer, prostate cancer, and brain cancer. In the early R&D stage, the focus is mainly on RDC drugs, with over 10 products in reserve, covering both diagnostic and therapeutic categories, providing patients with multiple treatment options, various methods, and globally leading integrated anti-tumor solutions.
Aiming at the global market, GRAND PHARMA is systematically advancing the clinical research and commercialization of its radiopharmaceutical products. In China, while the deployment of Yttrium-90 Microspheres injection (brand name "Yigantai") continues to expand, the product TLX591-CDx for prostate cancer diagnosis has entered the NDA stage. Overseas, GRAND PHARMA's SIR-Spheres Yttrium-90 Microspheres injection received early formal FDA approval in the U.S. in July 2025 for a new indication treating unresectable HCC, becoming the world's first and only selective internal radiation therapy product approved by the FDA for both unresectable HCC and colorectal cancer liver metastases. In August of the same year, it received CE marking in Europe, adding multiple liver cancer indications, further promoting comprehensive coverage of the product in the treatment of unresectable liver cancer, achieving a strategic expansion of its market space. Simultaneously, the company is collaborating with Chinese and international experts to develop other indications for the Yttrium-90 Microspheres injection and will use the "China-U.S. dual filing" international registration pathway to accelerate its global market expansion. Furthermore, international conferences have further validated the global R&D level of GRAND PHARMA's products. Research results for the company's globally innovative diagnostic radiopharmaceutical targeting Glypican-3 (GPC-3), GPN02006, received an oral presentation at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. This product has the potential to become the world's first GPC-3-targeted diagnostic RDC product for Hepatocellular Carcinoma (HCC).
In terms of production, GRAND PHARMA's Chengdu Wenjiang Radiopharmaceutical R&D and Production Base was fully operational in 2025. As the world's first closed-loop platform for the entire radiopharmaceutical industry chain, this base is one of the most comprehensive in terms of radionuclide variety and boasts the highest level of automation globally. It covers the entire chain from "isotope preparation - radiopharmaceutical R&D - clinical production - commercialization." The base's 14 high-standard GMP production lines enable multi-product, large-scale manufacturing, solving the "bottleneck" problem in radiopharmaceuticals. Achieving 100% self-production breaks the reliance on imports, further solidifying the foundation of GRAND PHARMA's radiopharmaceutical business, accelerating the implementation of global innovative R&D pipelines, promoting high-quality development of the radiopharmaceutical industry, cultivating high-value blockbuster products, and laying a solid foundation for the domestic localization of the company's radiopharmaceuticals.
Looking at the global radiopharmaceutical industry, competition in this track is no longer limited to the products themselves but is a comprehensive contest of radionuclide resources, manufacturing processes, and international clinical operation capabilities. While continuously enriching its radiopharmaceutical pipeline, GRAND PHARMA is also strengthening its proprietary platform construction, simultaneously building core capabilities in overseas clinical filing, self-developed platform construction, and large-scale production. This allows the company to rapidly introduce mature, high-quality global assets for domestic transformation and support local original innovation projects like GPN01530-2 to directly pursue overseas clinical trials with the FDA. Looking ahead, GRAND PHARMA is poised to leverage its globalized industrial system to output more innovative radiopharmaceuticals originating from China to serve cancer patients worldwide, deeply participating in the global transformation of the radiopharmaceutical industry.
Comments